v3.26.1
Consolidated Income Statements - EUR (€)
shares in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Consolidated Statement of Operations      
Supply revenues € 29,924,000 € 34,863,000  
Collaboration revenues 1,082,324,000 240,786,000 € 239,724,000
Total net revenues 1,112,248,000 275,649,000 239,724,000
Cost of sales (29,736,000) (34,863,000)  
Research and development expenses (459,421,000) (335,459,000) (241,294,000)
Sales and marketing expenses (6,100,000) (17,193,000) (5,676,000)
General and administrative expenses (147,333,000) (117,245,000) (128,289,000)
Impairment of the cell therapy business (228,112,000)    
Other operating income 53,493,000 40,773,000 47,272,000
Operating loss 295,039,000 (188,338,000) (88,263,000)
Fair value adjustments and net exchange differences (39,356,000) 95,795,000 16,252,000
Other financial income 48,051,000 91,128,000 80,249,000
Other financial expenses (2,863,000) (1,670,000) (2,613,000)
Profit / (Loss) (-) before tax 300,871,000 (3,085,000) 5,625,000
Income taxes 18,621,000 1,803,000 (9,613,000)
Net loss from continuing operations 319,492,000 (1,282,000) (3,988,000)
Net profit/(loss) (-) from discontinued operations, net of tax 1,392,000 75,364,000 215,685,000
Net profit / (loss) (-) 320,884,000 74,082,000 211,697,000
Net loss attributable to:      
Owners of the parent € 320,884,000 € 74,082,000 € 211,697,000
Basic earnings per share (in EUR per share) € 4.87 € 1.12 € 3.21
Diluted earnings per share (in EUR per share). 4.87 1.12 3.21
Basic and diluted loss per share from continuing operations (in EUR per share) 4.85 (0.02) (0.06)
Basic and Diluted loss per share from continuing operations (in EUR per share). € 4.85 € (0.02) € (0.06)
Weighted average number of shares - Basic (in '000 shares) 65,897 65,897 65,884
Weighted average number of shares - Diluted (in '000 shares) 65,897 65,897 65,884